In this article, we will look at the 10 Fastest Growing NASDAQ Stocks to Buy.
High growth stocks have once again taken center stage, and major asset managers argue that earnings momentum remains the decisive factor. In its 2026 Year-Ahead Investment Outlook, J.P. Morgan Asset Management notes that “profit growth has been impressive, tracking for four consecutive quarters of double-digit earnings growth”. The firm adds that “within stocks, we continue to see the biggest opportunities in structural rather than cyclical stories”, underscoring a preference for companies benefiting from secular tailwinds. Artificial intelligence remains a major catalyst behind this structural growth. J.P. Morgan writes that “the investment and adoption of AI continues to dominate the strength seen in U.S. economic and earnings growth”.
Vanguard’s 2026 Economic and Market Outlook echoes this constructive stance on growth, stating that “U.S. technology stocks could well maintain their momentum given the rate of investment and anticipated earnings growth.” At the same time, Vanguard cautions that “risks are growing amid this exuberance,” highlighting the need for selectivity.
Taken together, these outlooks suggest that fast-growing companies with sustained revenue acceleration and clear structural drivers remain compelling. With growth serving as the engine of returns, the focus shifts to businesses capable of compounding at elevated rates rather than merely benefiting from earnings multiple expansion. Against this backdrop, we’ll look at the 10 Fastest Growing NASDAQ Stocks to Buy.
Our Methodology
We used the Finviz screener to identify NASDAQ stocks that have achieved more than 50% sales growth over the past year and more than 50% growth over the past three years. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10. IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
On February 25, 2026, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced that the first patient has been enrolled in its Phase 1 dose escalation and expansion trial evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 ADC. The company plans to evaluate the safety, tolerability, and pharmacokinetics of IDE034 as a monotherapy in the Phase 1 study. It also intends to test combinations with agents targeting the DNA damage response pathway, including its proprietary PARG inhibitor IDE161. Dosing the first patient with IDE034 triggers a $5M milestone payment from Ideaya to Biocytogen under the companies’ option and license agreement.
On February 23, 2026, IDEAYA Biosciences announced the appointment of Theodora Ross to the newly created role of chief development officer. In this position, Ross will lead early clinical development for the company’s emerging oncology pipeline and help guide its long-term research and development strategy. Ross joins Ideaya from AbbVie, where she served as VP, head of early oncology R&D and site head for the Bay Area.
On February 17, 2026, IDEAYA Biosciences reported Q4 revenue of $10.88M, compared with consensus estimates of $5.95M. Collaboration revenue reflected performance obligations satisfied through December 31, 2025, related to research and development services recognized over time under the Servier exclusive license agreement for darovasertib. President and CEO Yujiro Hata said the company delivered “a strong quarter of clinical execution, clinical pipeline expansion and commercial readiness activities.” He cited highlights including completion of enrollment of 437 patients in the OptimUM-02 Phase 2/3 registrational trial, IND submissions for IDE034 and IDE574, and continued expansion of the company’s U.S. commercial organization ahead of upcoming topline progression-free survival results.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
9. Eos Energy Enterprises, Inc. (NASDAQ:EOSE)
On February 27, 2026, Eos Energy Enterprises, Inc. (NASDAQ:EOSE) saw mixed analyst actions following recent results. Stifel lowered the firm’s price target on the shares to $12 from $22 and maintained a Buy rating. On the same day, Guggenheim analyst Joseph Osha downgraded the stock to Neutral from Buy and removed the firm’s prior $20 price target after the release of Q4 results and the company’s 2026 outlook. The analyst said the company is making operational progress and could be successful over time, but management’s struggles with financial forecasting and communication remain a “challenge for valuation.”
On February 26, 2026, Eos Energy reported Q4 EPS of (84c), compared with consensus estimates of (24c). The company posted Q4 revenue of $58.0M, below the $93.69M consensus estimate. CEO Joe Mastrangelo said 2025 represented “a structural turning point for Eos,” highlighting accelerated production, expanded annual capacity to 2 GWh, record quarterly revenue, a cash position above $600M, and more than $240M in Q4 bookings across diversified markets. Mastrangelo added that while the company was “disappointed in not meeting revenue expectations,” execution improved as the year progressed and the company exited 2025 with operational momentum. He said the focus in 2026 will be on disciplined scale and margin improvement, including manufacturing efficiency, improved unit economics, and converting backlog into revenue.
Eos Energy Enterprises, Inc. (NASDAQ:EOSE) designs, develops, manufactures, and markets energy storage solutions for utility-scale, microgrid, and commercial and industrial applications in the United States.
8. CG Oncology, Inc. (NASDAQ:CGON)
On February 27, 2026, H.C. Wainwright raised the firm’s price target on CG Oncology, Inc. (NASDAQ:CGON) to $80 from $75 and maintained a Buy rating on the shares. The analyst said the company is advancing toward a biologics application submission for cretostimogene in high-risk non-muscle invasive bladder cancer, supported by strong durability and safety data, while also expanding into earlier treatment settings. The firm added that the Phase 3 PIVOT-006 trial in intermediate-risk NMIBC represents a key 2026 catalyst that could significantly broaden the company’s clinical and commercial opportunity.
On February 27, 2026, CG Oncology, Inc. (NASDAQ:CGON) reported FY25 EPS of ($2.08), compared with consensus estimates of (58c). The company reported revenue of $4.04M, above the $515,180 consensus estimate. Chairman and CEO Arthur Kuan said the company expects to report topline data from PIVOT-006 in the coming months, describing the study as “the first randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC.” Kuan added that the company believes it has the opportunity to establish a new standard in intermediate-risk NMIBC and highlighted cretostimogene’s “unique best-in-disease profile.” He also noted that results from CORE-008 Cohort CX in high-risk BCG-exposed patients evaluating cretostimogene in combination with gemcitabine are expected in the coming quarter.
CG Oncology, Inc. (NASDAQ:CGON) is a late-stage clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutics for patients with bladder cancer.
7. Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
On February 25, 2026, Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to $105 from $95 and maintained an Outperform rating following quarterly results. Management also provided first-time FY26 net product sales guidance of $670M–$700M for XDEMVY, representing a year-over-year increase of $230M driven by new patient demand, broad payer coverage, and effective direct-to-consumer efforts. The analyst said the outlook puts XDEMVY on track to achieve more than $2B in peak U.S. sales.
Also on February 25, 2026, Guggenheim raised its price target on Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to $90 from $87 and reiterated a Buy rating after the company reported what the firm described as “strong” 2025 results. The analyst noted that with 2026 sales guidance of $670M–$700M and only a small portion of the estimated 25M patient Demodex blepharitis market penetrated, the company appears “well-positioned for sustained growth.”
On February 23, 2026, Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) reported Q4 EPS of (20c), compared with consensus estimates of (13c). The company reported Q4 revenue of $151.67M, above the $144.56M consensus estimate. CEO and Chairman Bobak Azamian said XDEMVY has driven “a fundamental shift in eye care,” noting that the company has built broad access and established a growing franchise within two years of launch. Azamian added that the product validates the company’s model of integrating science, commercial execution, and strategic investment, and that the company plans to apply the same framework across its pipeline in ocular rosacea and Lyme disease prevention.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for eye care in the United States.
6. BridgeBio Pharma, Inc. (NASDAQ:BBIO)
On February 25, 2026, Truist analyst Danielle Brill raised the firm’s price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $95 from $86 and maintained a Buy rating on the shares. The analyst noted that the company had pre-announced Q4 Attruby sales of $146M in January, representing a 35% increase from Q3 and exceeding quarterly estimates. The performance was driven by an acceleration in the pace of new patient additions, which the analyst said appears to be continuing.
Also on February 25, 2026, Morgan Stanley analyst Sean Laaman raised the firm’s price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $98 from $96 and reiterated an Overweight rating after updating estimates following the company’s Q4 report.
On February 24, 2026, BridgeBio Pharma, Inc. (NASDAQ:BBIO) reported Q4 EPS of ($1.00), compared with consensus estimates of (67c). The company reported Q4 revenue of $154.18M, above the $149.07M consensus estimate. Co-Founder and CEO Neil Kumar said the company is reflecting on its progress over the past decade, highlighting three successful Phase 3 readouts delivered within a little over three months. Kumar said the results demonstrate the rigor of the company’s science and expressed hope that the progress could lead to six approved products as the company closes its first decade.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) discovers, develops, and delivers medicines for patients with genetic diseases.
5. SoundHound AI, Inc. (NASDAQ:SOUN)
On March 2, 2026, H.C. Wainwright lowered the firm’s price target on SoundHound AI, Inc. (NASDAQ:SOUN) to $20 from $26 and maintained a Buy rating on the shares. The firm said the company’s valuation may face near-term pressure despite the momentum seen in its Q4 report.
On February 27, 2026, Piper Sandler analyst James Fish lowered the firm’s price target on SoundHound AI, Inc. (NASDAQ:SOUN) to $9 from $11 and kept a Neutral rating on the shares. The analyst described the quarter as relatively mixed, with mostly in-line revenue, a profitability miss, and guidance that came in higher than expected. The firm also noted concerns around the required execution and potential M&A needed to bridge the gap, given the company’s current business run-rate.
On February 27, 2026, SoundHound AI, Inc. (NASDAQ:SOUN) reported Q4 EPS of (2c), in line with consensus estimates. The company reported Q4 revenue of $55.1M, above the $53.98M consensus estimate. SoundHound said that as traditional software faces disruption from artificial intelligence, businesses are increasingly partnering with AI-native companies. The company added that all key profit metrics improved and that it closed a record number of customer deals in the quarter as demand for enterprise-grade AI increased.
SoundHound AI, Inc. (NASDAQ:SOUN) develops independent voice artificial intelligence solutions that enable businesses across automotive, TV, IoT, and customer service industries to deliver conversational experiences to their customers in the United States and internationally.
4. ImmunityBio, Inc. (NASDAQ:IBRX)
On February 23, 2026, H.C. Wainwright raised its price target on ImmunityBio, Inc. (NASDAQ:IBRX) to $15 from $10 and maintained a Buy rating on the shares. The analyst said the recent European Union approval expands Anktiva’s footprint to 33 countries, “removing a major regulatory overhang” and opening a “meaningful incremental commercial opportunity.”
That same day, ImmunityBio reported Q4 EPS of (6c), compared to the (10c) consensus estimate. Q4 revenue was $38.29M versus consensus of $37.78M. President and CEO Richard Adcock said the company’s 2025 financial results reflect the growing clinical adoption of Anktiva “as a foundational backbone of immunotherapy for bladder cancer.” He noted that the partnership with Accord Healthcare deploys over 100 commercial professionals across 30 European countries and that collaboration with BioPharma & Cigalah supports commercial execution in Saudi Arabia and the broader MENA region. Adcock stated that with subsidiaries in Dublin and the Kingdom of Saudi Arabia, the company has infrastructure to support growth across all 33 countries where Anktiva is authorized. He added that the company remains focused on completing enrollment in its BCG-naive randomized trial with a BLA filing targeted by Q4 2026, expanding the Anktiva label into lung cancer and lymphopenia, and converting its “700% revenue growth trajectory” into durable value for shareholders.
ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company focused on developing and commercializing next-generation immunotherapies for cancer and infectious diseases.
3. CoreWeave, Inc. (NASDAQ:CRWV)
On February 27, 2026, Truist analyst Arvind Ramnani raised the price target on CoreWeave, Inc. (NASDAQ:CRWV) to $85 from $84 and maintained a Hold rating following Q4 results. The analyst said demand continues to significantly outpace supply but questioned “at what cost this will come,” adding there are more questions about the path to long-term sustainable profitability.
That same day, DA Davidson raised its price target to $125 from $110 and kept a Buy rating. The firm cited strong Q4 earnings driven by continued demand for AI compute and noted management’s forecast for 2026 capex in the $30B-$35B range compared to $14.9B in 2025. DA Davidson said that in a market where bringing capacity online is a key measure of success, capital expenditures and active power guidance serve as indicators of future performance.
On February 26, 2026, CoreWeave reported Q4 EPS of (89c), compared to the (68c) consensus estimate. Q4 revenue was $1.57B versus consensus of $1.53B. Chairman and Chief Executive Officer Michael Intrator said 2025 was “a defining year” as the company became “the fastest cloud in history to reach $5 billion in annual revenue,” adding that demand continues to intensify, and the company is ready to capture the opportunity ahead. Chief Financial Officer Nitin Agrawal said revenue backlog grew to $66.8 billion, “more than four times” where it began the year, providing visibility as the company scales into 2026 and beyond, and stated that CoreWeave is “well positioned for sustained hypergrowth.”
CoreWeave, Inc. (NASDAQ:CRWV) operates a cloud platform providing scaling, support, and acceleration for GenAI and builds infrastructure to support enterprise compute workloads.
2. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
On February 27, 2026, Guggenheim raised its price target on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) to $35 from $34 and maintained a Buy rating. The firm said it remains “encouraged” by the trajectory of Zoryve and the company’s efforts to maximize its value through commercialization.
On February 26, 2026, TD Cowen raised its price target to $35 from $30 and kept a Buy rating, updating its model following Q4 results as management increased full-year 2026 guidance.
On February 25, 2026, Arcutis Biotherapeutics reported Q4 EPS of 13c, compared to the 9c consensus estimate. Q4 revenue was $129.5M versus consensus of $113.03M. President and Chief Executive Officer Frank Watanabe said that in 2025 the company delivered more than 90% year-over-year growth in net product revenue, reflecting demand for ZORYVE, execution across multiple product launches leveraging its differentiated profile, and early penetration into the topical steroid market. Watanabe added that the company is entering the next phase of growth with a solid cash position and resources to invest in ZORYVE’s continued growth and pipeline advancement.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases.
1. Viridian Therapeutics, Inc. (NASDAQ:VRDN)
On February 27, 2026, RBC Capital lowered its price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $42 from $45 and maintained an Outperform rating. The analyst noted the company reported Q4 EPS and disclosed that veli’ PDUFA is scheduled for June 30, with preparations underway for a potential commercial launch in thyroid eye disease in mid-2026 if approved. RBC said it continues to favor the company’s positioning in 2026 as it could transition to the commercial stage and move closer to profitability.
On February 26, 2026, Jefferies raised its price target to $45 from $44 and kept a Buy rating. The firm said all key events remain on track and that investor focus is on the Phase 3 topline readout of subcutaneous elegrobart in REVEAL-1 in Q1, REVEAL-2 in Q2, and the PDUFA decision due June 30 for intravenous veligrotug under priority review.
That same day, Viridian Therapeutics reported Q4 EPS of ($1.08), compared to the ($1.00) consensus estimate. Q4 revenue was $132,000 versus the consensus of $15.75M. President and Chief Executive Officer Steve Mahoney said the company enters 2026 with continued execution momentum, highlighting the veligrotug BLA filing under Priority Review and a June 30, 2026, PDUFA target date. He added that the MAA submission to the EMA supports the global opportunity for veligrotug and that REVEAL-1 topline data for elegrobart is expected next month, with the goal of establishing veligrotug and elegrobart as foundational therapies for TED while advancing the broader pipeline.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) discovers, develops, and commercializes treatments for serious and rare diseases, including IGF-1R therapies for thyroid eye disease.
While we acknowledge the potential of VRDN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VRDN and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
